Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective

Objective This study aimed to estimate the cost-effectiveness of direct-acting antivirals (DAAs) among patients with non-genotype 1 for the eradication of hepatitis C virus (HCV) infection in China.Methods A decision-analytic Markov model was developed to estimate the lifetime costs, quality-adjuste...

Full description

Bibliographic Details
Main Authors: Li Yang, Xia Wei, Jingyu Zhao
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:BMJ Global Health
Online Access:https://gh.bmj.com/content/5/11/e003194.full